Renal allograft pathology in the sensitized patient

Current Opinion in Organ Transplantation

Volumn 18, Issue 3, 2013, Pages 327-336

  Cornell, Lynn D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibody mediated rejection; Arteriosclerosis; Humoral rejection; Transplant

Indexed keywords

ALLOANTIBODY; ANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C4D; DONOR SPECIFIC ANTIBODY; ECULIZUMAB; UNCLASSIFIED DRUG;

ACUTE ANTIBODY MEDIATED REJECTION; ACUTE HUMORAL REJECTION; ANTIBODY MEDIATED REJECTION; CHRONIC ANTIBODY MEDIATED REJECTION; COMPLEMENT SYSTEM; DISEASE ASSOCIATION; GLOMERULOPATHY; GRAFT FAILURE; GRAFT REJECTION; HUMAN; INHIBITION KINETICS; INJURY; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROSCLEROSIS; PERITUBULAR CAPILLARY BASEMENT MEMBRANE MULTILAMINATION; RENAL ALLOGRAFT INJURY; RENAL ALLOGRAFT PATHOLOGY; RENAL GRAFT DYSFUNCTION; REVIEW; TERMINAL COMPLEMENT PATHWAY; TISSUE INJURY; TRANSPLANT GLOMERULOPATHY; ALLOTRANSPLANTATION; BLOOD; DONOR; IMMUNOLOGY; PATHOLOGY;

GRAFT REJECTION; HUMANS; ISOANTIBODIES; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

MLCS; MLOWN;

EID: 84879990107     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283614c5a     Document Type: Review

References (75)

1. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86:464-470.
2. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43:1333-1338.
3. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10:2208-2214.
4. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13:779-787.
5. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12:574-582.
6. Cecka JM. Current methodologies for detecting sensitization to HLA antigens. Curr Opin Organ Transplant 2011; 16:398-403.
7. Gebel HM, Bray RA. The evolution and clinical impact of human leukocyte antigen technology. Curr Opin Nephrol Hypertens 2010; 19:598-602.
8. Claas FH. Clinical relevance of circulating donor-specific HLA antibodies. Current Opin Organ Transplant 2010; 15:462-466.
9. Zeevi A, Lunz JG 3rd, Shapiro R, et al. Emerging role of donor-specific antihuman leukocyte antigen antibody determination for clinical management after solid organ transplantation. Human Immunol 2009; 70:645-650.
10. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: risk and prognosis related to antihuman leukocyte antigen class II antibody levels. Transplantation 2008; 86:681-685.
11. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2011 Annual Data Report: Kidney. Am J Transplant 2013; 13:11-46.
12. Cecka JM. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant 2010; 10:26-29.
13. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
14. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6:1841-1847.
15. Lederer SR, Kluth-Pepper B, Schneeberger H, et al. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 2001; 59:334-341.
16. Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13:76-85.
17. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11:2405-2413.
18. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9:527-535.
19. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9:2520-2531.
20. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21:1398-1406.
21. Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012; 23:2061-2071.
22. Wasowska BA, Lee CY, Halushka MK, Baldwin WM 3rd. New concepts of complement in allorecognition and graft rejection. Cell Immunol 2007; 248:18-30.
23. Nickeleit V, Zeiler M, Gudat F, et al. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13:242-251.
24. Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. Nature reviews. Nephrology 2012; 8:670-678.
25. Kuo HH, Morrell CN, Baldwin WM 3rd. Alloantibody induced platelet responses in transplants: potent mediators in small packages. Hum Immunol 2012; 73:1233-1238.
26. Kirk AD, Morrell CN, Baldwin WM 3rd. Platelets influence vascularized organ transplants from start to finish. Am J Transplant 2009; 9:14-22.
27. Chapman LM, Aggrey AA, Field DJ, et al. Platelets present antigen in the context of MHC class I. J Immunol 2012; 189:916-923.
28. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3:708-714.
29. Karasova D, Sebkova A, Havlickova H, et al. Influence of 5 major Salmonella pathogenicity islands on NK cell depletion in mice infected with Salmonella enterica serovar Enteritidis. BMC microbiology 2010; 10:75.
30. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10:1812-1822.
31. Wills MR, Ashiru O, Reeves MB, et al. Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J Immunol 2005; 175:7457-7465.
32. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013;381:313-319.
33. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8:2684-2694.
34. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355:1233-1243.
35. Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25:1256-1264.
36. Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization (NCT01399593). In: ClinicalTrials.gov. US National Library of Medicine; 2012. http:// clinicaltrials.gov/ct2/show/NCT01399593
37. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9:231-235.
38. Gonzalez-Roncero F, Suner M, Bernal G, et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 2012; 44:2690-2694.
39. Liptak P, Kemeny E, Morvay Z, et al. Peritubular capillary damage in acute humoral rejection: an ultrastructural study on human renal allografts. Am J Transplant 2005; 5:2870-2876.
40. Mihatsch MJ, Kyo M, Morozumi K, et al. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998; 49:356-363.
41. Bartel G, Wahrmann M, Exner M, et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transplant 2008; 8:41-49.
42. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7:1743-1752.
43. Cornell LD, Smith RN, Colvin RB. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol 2008; 3:189-220.
44. Ivanyi B, Kemeny E, Szederkenyi E, et al. The value of electron microscopy in the diagnosis of chronic renal allograft rejection. Mod Pathol 2001; 14:1200-1208.
45. Wavamunno MD, O'Connell PJ, Vitalone M, et al. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am J Transplant 2007; 7:2757-2768.
46. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3:1017-1023.
47. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70:887-895.
48. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76:631-636.
49. Baid-Agrawal S, Farris AB 3rd, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011; 80:879-885.
50. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7:2124-2132.
51. Liapis G, Singh HK, Derebail VK, et al. Diagnostic significance of peritubular capillary basement membrane multilaminations in kidney allografts: old concepts revisited. Transplantation 2012; 94:620-629.
52. Lerut E, Naesens M, Kuypers DR, et al. Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year. Transplantation 2007; 83:1416-1422.
53. Cosio FG, Lager DJ, Lorenz EC, et al. Significance and implications of capillaritis during acute rejection of kidney allografts. Transplantation 2010; 89:1088-1094.
54. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9:2561-2570.
55. Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9:2312-2323.
56. Hidalgo LG, Sellares J, Sis B, et al. Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant 2012; 12:1180-1191.
57. Sellares J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 2013.
58. Doubrovina ES, Doubrovin MM, Vider E, et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003; 171:6891-6899.
59. Hirohashi T, Chase CM, Della Pelle P, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12:313-321.
60. Hirohashi T, Uehara S, Chase CM, et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant 2010; 10:510-517.
61. Hanvesakul R, Kubal C, Moore J, et al. KIR and HLA-C interactions promote differential dendritic cell maturation and is a major determinant of graft failure following kidney transplantation. PloS one 2011; 6:e23631.
62. Reeve J, Sellares J, Mengel M, et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant 2013; 13: 645-655.
63. Hill GS, Nochy D, Loupy A. Accelerated arteriosclerosis: a form of transplant arteriopathy. Curr Opin Organ Transplant 2010; 15:11-15.
64. Hill GS, Nochy D, Bruneval P, et al. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011; 22:975-983.
65. Cornell LD, Gloor JM, Raghavaiah S, et al. Chronic antibody mediated histologic changes in positive-crossmatch kidney transplants receiving early C5 blockade. Am J Transplant 2012; 12:450-1450.
66. Truong L, Gelfand J, D'Agati V, et al. De novo membranous glomerulonephropathy in renal allografts: a report of ten cases and review of the literature. Am J Kidney Dis 1989; 14:131-144.
67. Pirson Y, Ghysen J, Cosyns JP, et al. Aetiology and prognosis of de novo graft membranous nephropathy. Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress 1985; 21:672-676.
68. Lim BJ, Kim MS, Kim YS, et al. C4d deposition and multilayering of peritubular capillary basement membrane in posttransplantation membranous nephropathy indicate its association with antibody-mediated injury. Transplant Proc 2012; 44:619-620.
69. Collins AB, Satoskar AA, Beck LH, Jr., et al. De novo membranous glomerulonephritis (MGN) is immunologically distinct from idiopathic MGN and associated with C4d deposition and chronic humoral rejection [abstract]. In: 11th Banff Conference on Allograft Pathology, Enghien-les-Bains, France, June 2011.
70. Lerut E, Kuypers DR, Verbeken E, et al. Acute rejection in noncompliant renal allograft recipients: a distinct morphology. Clin Transplant 2007; 21: 344-351.
71. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12:388-399.
72. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with micro-vascular pathology and late graft failure. Am J Transplant 2009; 9:2532-2541.
73. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157-1167.
74. Ginevri F, Nocera A, Comoli P, et al. Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant 2012; 12:3355-3362.
75. Shellmer DA, Dabbs AD, Dew MA. Medical adherence in pediatric organ transplantation: what are the next steps? Curr Opin Organ Transplant 2011; 16:509-514.